Patient Characteristics and Survival Outcomes of Lenalidomide ...

Patient characteristics and survival outcomes of Lenalidomide exposed non-refractory vs. lenalidomide refractory multiple myeloma patients.

REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL ...

The increased use of lenalidomide (Len) containing regimens in the frontline treatment setting has led to a higher number of Len-refractory ...

Characteristics and Outcomes of Patients With Relapsed/Refractory ...

In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, ...

Characteristics and Outcomes in Patients with Lenalidomide ...

13.8% of all eligible index lines were triple-class refractory; 58.9% received stem cell transplant prior to T0. The most common treatment ...

Characteristics and Outcomes of Patients With Relapsed/Refractory ...

The increasing use of lenalidomide (Len) in first-line (1L) therapy of multiple myeloma (MM) has led to a significant proportion of patients becoming ...

The survival impact of maintenance lenalidomide: an analysis of real ...

Response rates were deeper in the LM cohort including nCR/CR (52.0% vs. 45.2%, P=0.05) and ≥VGPR (93.9% vs. 80.7%, P<0.01). The PFS benefit of ...

Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in ...

Request PDF | On Nov 15, 2022, Roman Hajek and others published Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs.

Outcomes of patients with multiple myeloma refractory to standard ...

For the next lenalidomide-containing line of therapy after first relapse, the median PFS for the Standard Dose Refractory group was 8 months (95 ...

Lenalidomide maintenance versus observation for patients with ...

The results of the Myeloma XI trial contribute to a body of evidence that suggests that the use of lenalidomide as maintenance therapy should be ...

p944: real-world patient characteristics and survival outcomes of ...

The toxicity was similar to the data reported from clinical trials with no new safety alerts. Conclusions: We conclude that lenalidomide based triplets (DRD, ...

Defining Unmet Need Following Lenalidomide Refractoriness

114 patients (72% of 158 evaluable) became refractory to lenalidomide. The overall survival (OS) after lenalidomide failure was 14.7 months ...

Paper: Comparison of Response and Survival Outcomes in Standard

Introduction: The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is highly effective for newly diagnosed myeloma (NDMM) patients. However, the ...

Real-world patient characteristics and treatment outcomes among ...

There is limited real-world evidence that describes patients with newly diagnosed multiple myeloma (NDMM) treated with the bortezomib, ...

The Effect of Duration of Lenalidomide Maintenance and Outcomes ...

b The median overall survival (OS) in lenalidomide refractory was 6.4 (95% CI: 2.9, 9.8) years (5-year OS: 60%) in patients who were ...

Clinical characteristics and survival outcomes of patients with ...

The overall response rate after induction was 69%, 28% complete remission and progressive disease was observed in 100 (29%) patients. 126 (36%) ...

Randomized Trial of Lenalidomide Versus Observation in ...

Seven deaths have occurred, resulting in a 5-year overall survival rate of 88% (95% CI, 78% to 98%; Appendix Fig A2, online only). Three-year ...

REAL‐WORLD PATIENT CHARACTERISTICS AND SURVIVAL ...

P944: REAL‐WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED ...

Updated Outcomes and Impact of Age With Lenalidomide and Low ...

Median overall survival was longer with Rd continuous than with MPT, including a 14-month difference in patients age older than 75 years.

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients ...

The superiority of continuous lenalidomide–dexamethasone over MPT for both progression-free survival and overall survival was noted in most ...

Lenalidomide Data in Multiple Myeloma Patients Demonstrate ...

The combined survival rate at 1 year was 96.5% with lenalidomide/LDD vs 86% with lenalidomide/HDD, more than a 10% improvement in survival.